<DOC>
	<DOC>NCT00568464</DOC>
	<brief_summary>The purpose of this clinical trial was to evaluate the efficacy and tolerability of the sequential therapy of VCD/IE in the patients with ESFT.</brief_summary>
	<brief_title>Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)</brief_title>
	<detailed_description>80-90% patients of ESFT will develope disease progression during the period of local treatment (surgery or radiation). The survival has been improved in these 30 years due to chemotherapy. VCD/IE is widely used in the world for the patients with ESFT, but it is rarely used in China due to its high dosage.</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma, Ewing</mesh_term>
	<criteria>Age range 1065 years old Histological confirmed ESFT No previous therapy ECOG performance status less than 2 Life expectancy of more than 12 weeks Normal laboratory values: hemoglobin&gt;8.0g/dl, neutrophil&gt;2×109/L, platelet &gt; 80×109/L, Hb &gt; 80×1012/L, serum creatine &lt; 1×upper limitation of normal(ULN), serum bilirubin &lt; 1.5×ULN, ALT and AST &lt; 2.5×ULN Pregnant or lactating women Received treatment for the disease previously Serious uncontrolled diseases and intercurrent infection The evidence of CNS metastasis and bone marrow involvement History of other malignancies except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix History of allergy to the drugs in this trial Abnormal LVEF level</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>ESFT (Ewing's sarcoma family of tumors)</keyword>
	<keyword>Response rate</keyword>
	<keyword>TTP</keyword>
	<keyword>OS</keyword>
	<keyword>Toxicity</keyword>
</DOC>